CLAIM AMENDMENTS

1. (Original) An antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides from SEQ ID NO:1 for use in the treatment of cancer in a mammal in need of such therapy.

2. (Original) The antisense oligonucleotide according to claim 1, wherein said cancer is a solid tumour.

3. (Original) The antisense oligonucleotide according to claim 1, wherein said cancer is a leukaemia.

4. (Original) The antisense oligonucleotide according to claim 2, wherein said solid tumour is drug-resistant.

5. (Original) The antisense oligonucleotide according to claim 2, wherein said solid tumour is metastatic.

6. (Original) The antisense oligonucleotide according to any one of claims 2, 4 or 5, wherein said solid tumour is a carcinoma.

7. (Original) The antisense oligonucleotide according to any one of claims 2, 4 or 5, wherein said solid tumour is a sarcoma.

8. (Original) The antisense oligonucleotide according to any one of claims 2, 4 or 5, wherein said solid tumour is a lymphoma.

9. (Original) The antisense oligonucleotide according to any one of claims 2, 4 or 5, wherein said solid tumour is an ovarian tumour, a renal tumour, a cervical tumor or a brain tumour.

10. (Original) The antisense oligonucleotide according to claim 7, wherein said sarcoma is fibrosarcoma.

11. (Original) The antisense oligonucleotide according to claim 7, wherein said lymphoma is a non-Hodgkin's lymphoma.

12. (Original) The antisense oligonucleotide according to claim 3, wherein said leukaemia is acute myeloid leukaemia or chronic myeloid leukaemia.

13. (Original) An antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides from SEQ ID NO:1 for use in combination with one or more chemotherapeutic agents in the treatment of cancer in a mammal in need of such therapy.

14. (Original) The antisense oligonucleotide according to claim 13, wherein said cancer is a solid tumour.

15. (Original) The antisense oligonucleotide according to claim 13, wherein said cancer is a leukaemia.

16. (Original) The antisense oligonucleotide according to claim 14, wherein said solid tumour is drug-resistant.

17. (Original) The antisense oligonucleotide according to claim 14, wherein said solid tumour is metastatic.

18. (Original) The antisense oligonucleotide according to any one of claims 14, 16 or 17, wherein said solid tumour is a carcinoma.

19. (Original) The antisense oligonucleotide according to any one of claims 14, 16 or 17, wherein said solid tumour is a sarcoma.

20. (Original) The antisense oligonucleotide according to any one of claims 14, 16 or 17, wherein said solid tumour is a lymphoma.

21. (Original) The antisense oligonucleotide according to any one of claims 14, 16, 17 or 18, wherein said solid tumour is selected from the group of: renal tumour, breast

tumour, lung tumour, prostate tumour, colon tumour, melanoma, ovarian tumour, cervical tumour, brain tumour, liver tumour, colorectal tumour, pancreatic tumour, genitourinary tumour, gall bladder tumour, head and neck tumour, oesophageal tumour and biliary duct tumour.

22. (Original) The antisense oligonucleotide according to any one of claims 14, 16, 17 or 18, wherein said solid tumour is selected from the group of: renal tumour, breast tumour, lung tumour, prostate tumour, colon tumour, melanoma, ovarian tumour, cervical tumour, brain tumour and liver tumour.

23. (Original) The antisense oligonucleotide according to any one of claims 14, 16, 17 or 18, wherein said solid tumour is selected from the group of: solid tumours, renal tumour, breast tumour, cervical tumor, lung tumour, prostate tumour and colon tumour.

24. (Original) The antisense oligonucleotide according to claim 15, wherein said leukaemia is acute myeloid leukaemia, acute promyelocytic leukemia or chronic myeloid leukaemia.

25. (Original) The antisense oligonucleotide according to claim 15, wherein said leukaemia is acute myeloid leukaemia.

26. (Original) The antisense oligonucleotide according to any one of claims 13 to 25, wherein said one or more chemotherapeutic agents is selected from the group of: capecitabine, 5-fluorouracil, vinblastine, cytarabine, taxol, docetaxel, mitoxantrone, oxaliplatin, mitomycin, irinotecan, dacarbazine, cisplatin, hydroxyurea, gemcitabine, prednisone, idarubicin, etoposide, fludarabine, filgrastin, carboplatin, mitomycin C, paclitaxel and interleukin-2 or a combination thereof.

27. (Original) The antisense oligonucleotide according to any one of claims 13 to 25, wherein said one or more chemotherapeutic agents is selected from the group of: capecitabine, 5-fluorouracil, cytarabine, taxol, docetaxel, mitoxantrone, oxaliplatin,

mitomycin, irinotecan, dacarbazine, cisplatin and gemcitabine, or a combination thereof.

28. (Original) The antisense oligonucleotide according to any one of claims 13 to 25, wherein said one or more chemotherapeutic agents is selected from the group of: capecitabine, cytarabine, taxol, docetaxel, oxaliplatin and gemcitabine, or a combination thereof.

29. (Original) The antisense oligonucleotide according to any one of claims 1 to 28, wherein said antisense oligonucleotide comprises a sequence as set forth in SEQ ID NO:1.

30. (Original) The antisense oligonucleotide according to any one of claims 1 to 28, wherein said antisense oligonucleotide consists of a sequence as set forth in SEQ ID NO:1.

31. (Original) The antisense oligonucleotide according to any one of claims 1 to 30, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

32. (Original) The antisense oligonucleotide according to any one of claims 1 to 31, wherein said mammal is a human

33. (Original) An antisense oligonucleotide of between 20 and 100 nucleotides in length comprising the sequence as set forth in SEQ ID NO:1 for use in combination with one or more chemotherapeutic agents in the treatment of a human having a cancer selected from the group of: a solid tumour, lymphoma, renal cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, cervical cancer, colon cancer and leukaemia.

34. (Original) The antisense oligonucleotide according to claim 33, wherein said antisense oligonucleotide consists of a sequence as set forth in SEQ ID NO:1.

35. (Original) The antisense oligonucleotide according to claim 33 or 34, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

36. (Original) The antisense oligonucleotide according to any one of claims 33 to 35, wherein said one or more chemotherapeutic agent is gemcitabine and said cancer is a solid tumour.

37. (Original) The antisense oligonucleotide according to any one of claims 33 to 35, wherein said one or more chemotherapeutic agent is irinotecan or mitomycin C and said cancer is colon cancer.

38. (Original) The antisense oligonucleotide according to any one of claims 33 to 35, wherein said one or more chemotherapeutic agent is paclitaxel or cisplatin and said cancer is breast cancer.

39. (Original) The antisense oligonucleotide according to any one of claims 33 to 35, wherein said one or more chemotherapeutic agent is docetaxel and said cancer is prostate cancer.

40. (Original) The antisense oligonucleotide according to any one of claims 33 to 35, wherein said one or more chemotherapeutic agent is a combination of oxaliplatin and capecitabine and said cancer is colon cancer.

41. (Original) The antisense oligonucleotide according to any one of claims 33 to 35, wherein said one or more chemotherapeutic agent is cytarabine and said cancer is acute myeloid leukaemia.

42. (Original) The antisense oligonucleotide according to claim 37, wherein said renal cancer is advanced renal cancer.

43. (Original) The antisense oligonucleotide according to claim 37, wherein said renal cancer is metastatic renal cancer.

44. (Original) The antisense oligonucleotide according to any one of claims 37, 42 or 43, wherein said antisense oligonucleotide is formulated for administration to said mammal at a dose of between about 124.8 mg/m^2/day and about 274.2 mg/m^2/day.

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Cancelled)

49. (Cancelled)

50. (Cancelled)

51. (Cancelled)

52. (Cancelled)

53. (Cancelled)

54. (Cancelled)

55. (Cancelled)

56. (Cancelled)

57. (New) A dosage unit formulation comprising an antisense oligonucleotide of between about 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides from SEQ ID NO:1 in an amount effective to provide a dose of between about 6.0 mg/m^2/day and about 356.5 mg/m^2/day to a human and a pharmaceutically acceptable carrier.

58. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide is between about 7 and 50 nucleotides in length.

59. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide is between about 15 and 25 nucleotides in length.

60. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide is between about 20 and 100 nucleotides in length.

61. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide comprises a sequence as set forth in SEQ ID NO:1.

62. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide consists of a sequence as set forth in SEQ ID NO:1.

63. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

64. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide is a modified or substituted oligonucleotide.

65. (New) The dosage unit formulation according to claim 57, wherein said dosage unit formulation is for the treatment of a solid tumour in said human.

66. (New) The dosage unit formulation according to claim 65, wherein said solid tumour is drug-resistant.

67. (New) The dosage unit formulation according to claim 65, wherein said solid tumour is metastatic.

68. (New) The dosage unit formulation according to claim 65, wherein said solid tumour is a prostate tumour.

69. (New) The dosage unit formulation according to claim 68, wherein said prostate tumour is a metastatic prostate tumour.

70. (New) The dosage unit formulation according to claim 68, wherein said prostate tumour is a hormone refractory prostate tumour.

71. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide is in an amount effective to provide a dose of between about 124.8 mg/m^2/day and about 356.5 mg/m^2/day to said human.

72. (New) The dosage unit formulation according to claim 57, wherein said antisense oligonucleotide is in an amount effective to provide a dose of between about 124.8 mg/m^2/day and about 210.9 mg/m^2/day to said human.

73. (New) The dosage unit formulation according to claim 57, wherein said dosage unit formulation is formulated for parenteral administration.

74. (New) The dosage unit formulation according to claim 57, wherein said dosage unit formulation is formulated for intravenous administration.

75. (New) The dosage unit formulation according to claim 57, wherein said dosage unit formulation is an injectable formulation.

76. (New) The dosage unit formulation according to claim 65, wherein said dosage unit formulation is administered in combination with one or more chemotherapeutics.

77. (New) The dosage unit formulation according to claim 76, wherein said solid tumour is a prostate tumour and said one or more chemotherapeutics is docetaxel.

78. (New) The dosage unit formulation according to claim 77, wherein said docetaxel is administered to said human at a dose of between about 45 mg/m^2/day and about 75 mg/m^2/day.

79. (New) The dosage unit formulation according to claim 77, wherein said docetaxel is administered to said human at a dose of between about 60 mg/m^2/day and about 75 mg/m^2/day.

80. (New) A method of treating a solid tumour in a human comprising administering to said human the dosage unit formulation according to claim 57.

81. (New) The method according to claim 80, wherein said antisense oligonucleotide is between about 7 and 50 nucleotides in length.

82. (New) The method according to claim 80, wherein said antisense oligonucleotide is between about 15 and 25 nucleotides in length.

83. (New) The method according to claim 80, wherein said antisense oligonucleotide is between about 20 and 100 nucleotides in length.

84. (New) The method according to claim 80, wherein said antisense oligonucleotide comprises a sequence as set forth in SEQ ID NO:1.

85. (New) The method according to claim 80, wherein said antisense oligonucleotide consists of a sequence as set forth in SEQ ID NO:1.

86. (New) The method according to claim 80, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

87. (New) The method according to claim 80, wherein said antisense oligonucleotide is a modified or substituted oligonucleotide.

88. (New) The method according to claim 80, wherein said antisense oligonucleotide is in an amount effective to provide a dose of between about 124.8 mg/m^2/day and about 356.5 mg/m^2/day to said human.

89. (New) The method according to claim 80, wherein said antisense oligonucleotide is in an amount effective to provide a dose of between about 124.8 mg/m^2/day and about 210.9 mg/m^2/day to said human.

90. (New) The method according to claim 80, wherein said dosage unit formulation is administered parenterally.

91. (New) The method according to claim 80, wherein said dosage unit formulation is administered intravenously.

92. (New) The method according to claim 80, wherein said dosage unit formulation is administered by continuous intravenous infusion.

93. (New) The method according to claim 80, wherein said dosage unit formulation is administered in combination with one or more chemotherapeutics.

94. (New) The method according to claim 93, wherein said solid tumour is a prostate tumour and said one or more chemotherapeutics is docetaxel.

95. (New) The method according to claim 94, wherein said docetaxel is administered to said human at a dose of between about 45 mg/m^2/day and about 75 mg/m^2/day.

96. (New) The method according to claim 94, wherein said docetaxel is administered to said human at a dose of between about 60 mg/m^2/day and about 75 mg/m^2/day.